Latest News About Mark Cuban Cost Plus Drug Company

Here’s a quick update on Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) based on recent reporting up to 2026.

• What it is: An online pharmacy co-founded by Mark Cuban and Dr. Alex Oshmyansky aiming to lower prescription drug costs by selling generic meds directly to consumers with price transparency, bypassing some traditional middlemen in the supply chain.[4][7]
• Public reception and impact: The company has generated substantial attention for its model and claims of significant savings, but analysts and clinicians note mixed progress in broader market penetration and in serving complex or brand-name drugs; challenges include pharmacist adoption, formulary integration, and competition with established PBMs and insurers.[3][8][4]
• Current stance and strategy: Cost Plus Drugs has discussed expanding beyond generics, exploring manufacturing capabilities, and pursuing partnerships with insurers or employers to broaden access, while also contending with regulatory and logistical hurdles common to direct-to-consumer pharma models.[5][7][4]
• Recent coverage highlights: Media profiles, industry analyses, and interviews continue to question the degree of disruption achieved relative to expectations, while acknowledging ongoing efforts to push for transparency and lower list prices.[7][3][4]

If you’d like, I can pull the latest specific headlines from major outlets and summarize any major developments, provide a short timeline, or compare Cost Plus Drugs’ pricing model to traditional PBMs.